SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

688266

CNE100003RP1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 22/05/2024 BST			5-day change	1st Jan Change
54.76 ^CNY	-3.30%		+0.31%	+3.44%

04-19	Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-12	Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials	MT

Suzhou Zelgen Biopharmaceuticals Co., Ltd. Announces Earnings Results for First Three Quarters of 2020

October 28, 2020

Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced earnings results for first Three Quarters of 2020. For the period, the company reported basic loss per share of CNY 0.98 .

Latest news about Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-19	CI
Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials	04-12	MT
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Zelgen Biopharmaceuticals Grants Yuanda Life Unit Marketing Rights for Recombinant Human Thrombin	12-08	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Zelgen Biopharma’s Phase III Trial of Thyroid Cancer Treatment Yields Positive Results	19/09/23	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(XSSC:688266) added to S&P Global BMI Index	18/09/23	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23	CI
Zelgen Biopharmaceuticals Gets Nod for China Clinical Trial of Solid Tumor Drug	31/07/23	MT
Apeloa Pharma Forms Strategic Drug Alliance With Zelgen Biopharma	13/06/23	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	21/04/23	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that it has received CNY 1.45529 billion in funding	20/04/23	CI
Zelgen Biopharma Gets Nod for Clinical Trials of Tumor Drug	19/04/23	MT
Zelgen Biopharmaceuticals Wins FDA Nod to Trial Lung Cancer Drug	11/04/23	MT
Zelgen Biopharmaceuticals Certified as High-Tech Enterprise in China	03/03/23	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	13/10/22	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	18/08/22	CI
Zelgen Biopharma Wins Nod to Launch Clinical Trial of Tumor Treatment	17/08/22	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(SHSE:688266) dropped from Shanghai Stock Exchange Health Care Sector Index	10/06/22	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/04/22	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	23/02/22	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that it expects to receive CNY 2.86285 billion in funding	24/11/21	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/10/21	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	20/08/21	CI
111 : Partners With Suzhou Zelgen to Develop Liver Cancer Patients Platform in China	03/08/21	MT

Chart Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Duration

Period

Chart Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

More charts

Suzhou Zelgen Biopharmaceuticals Co Ltd is a China-based company mainly engaged in pharmaceutical manufacturing. The Company's main products include pharmaceuticals and pharmaceutical intermediates and raw materials. Its products are mainly applied in the fields of tumors, bleeding and blood diseases, immune inflammatory diseases and hepatobiliary diseases. The Company operates in the domestic market and overseas markets.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

54.76 CNY

Average target price

64 CNY

Spread / Average Target

+16.87%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD.	+3.44%	2.07B
ELI LILLY AND COMPANY	+37.85%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.52%	369B
MERCK & CO., INC.	+20.03%	332B
ABBVIE INC.	+2.59%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.16%	168B

Other Pharmaceuticals